Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Cobalt(II) and (I) Complexes of Diphosphine-Ketone Ligands: Catalytic Activity in Hydrosilylation Reactions.

Verhoeven DGA, Kwakernaak J, van Wiggen MAC, Lutz M, Moret ME.

Eur J Inorg Chem. 2019 Feb 7;2019(5):660-667. doi: 10.1002/ejic.201801221. Epub 2019 Jan 28.

2.

Single dose combination nanovaccine provides protection against influenza A virus in young and aged mice.

Ross K, Senapati S, Alley J, Darling R, Goodman J, Jefferson M, Uz M, Guo B, Yoon KJ, Verhoeven D, Kohut M, Mallapragada S, Wannemuehler M, Narasimhan B.

Biomater Sci. 2019 Feb 26;7(3):809-821. doi: 10.1039/c8bm01443d.

PMID:
30663733
3.

Neutropenia management in patients receiving myelosuppressive polychemotherapy for early breast cancer in Belgium: BRONS study results.

Catala G, Mebis J, Jerusalem G, Verhoeven D, Awada A, Bols A, Somers L, Van Den Broeck A, Duhoux FP, Machiels JP.

Acta Clin Belg. 2019 Jan 4:1-8. doi: 10.1080/17843286.2018.1563735. [Epub ahead of print]

PMID:
30609907
4.

Immunometabolism and innate immunity in the context of immunological maturation and respiratory pathogens in young children.

Verhoeven D.

J Leukoc Biol. 2019 Aug;106(2):301-308. doi: 10.1002/JLB.MR0518-204RR. Epub 2019 Jan 3. Review.

PMID:
30605225
5.

Influence of Immunological Maturity on Respiratory Syncytial Virus-Induced Morbidity in Young Children.

Verhoeven D.

Viral Immunol. 2019 Mar;32(2):76-83. doi: 10.1089/vim.2018.0121. Epub 2018 Nov 30. Review.

PMID:
30499759
6.

UCBG 2-08: 5-year efficacy results from the UNICANCER-PACS08 randomised phase III trial of adjuvant treatment with FEC100 and then either docetaxel or ixabepilone in patients with early-stage, poor prognosis breast cancer.

Campone M, Lacroix-Triki M, Roca L, Spielmann M, Wildiers H, Cottu P, Kerbrat P, Levy C, Desmoulins I, Bachelot T, Winston T, Eymard JC, Uwer L, Duhoux FP, Verhoeven D, Jaubert D, Coeffic D, Orfeuvre H, Canon JL, Asselain B, Martin AL, Lemonnier J, Roché H.

Eur J Cancer. 2018 Nov;103:184-194. doi: 10.1016/j.ejca.2018.06.025. Epub 2018 Sep 26.

PMID:
30267987
7.

In vitro-Induced Human IL-10+ B Cells Do Not Show a Subset-Defining Marker Signature and Plastically Co-express IL-10 With Pro-Inflammatory Cytokines.

Lighaam LC, Unger PA, Vredevoogd DW, Verhoeven D, Vermeulen E, Turksma AW, Ten Brinke A, Rispens T, van Ham SM.

Front Immunol. 2018 Sep 5;9:1913. doi: 10.3389/fimmu.2018.01913. eCollection 2018.

8.

Versatile Coordination and C-C Coupling of Diphosphine-Tethered Imine Ligands with Ni(II) and Ni(0).

Verhoeven DGA, Negenman HA, Orsino AF, Lutz M, Moret ME.

Inorg Chem. 2018 Sep 4;57(17):10846-10856. doi: 10.1021/acs.inorgchem.8b01478. Epub 2018 Aug 16.

9.

Increased risk of hematologic malignancies in primary immunodeficiency disorders: opportunities for immunotherapy.

Verhoeven D, Stoppelenburg AJ, Meyer-Wentrup F, Boes M.

Clin Immunol. 2018 May;190:22-31. doi: 10.1016/j.clim.2018.02.007. Epub 2018 Feb 27. Review.

10.

Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial.

Neven P, Jongen L, Lintermans A, Van Asten K, Blomme C, Lambrechts D, Poppe A, Wildiers H, Dieudonné AS, Brouckaert O, Decloedt J, Berteloot P, Verhoeven D, Joerger M, Vuylsteke P, Wynendaele W, Casteels M, Van Huffel S, Lybaert W, Van Ginderachter J, Paridaens R, Vergote I, Dezentjé VO, Van Calster B, Guchelaar HJ.

Clin Cancer Res. 2018 May 15;24(10):2312-2318. doi: 10.1158/1078-0432.CCR-17-3028. Epub 2018 Feb 19.

11.

First-line vs second-line fulvestrant for hormone receptor-positive advanced breast cancer: A post-hoc analysis of the CONFIRM study.

Di Leo A, Jerusalem G, Torres R, Verhoeven D, Pendergrass K, Malorni L, Lichfield J, Martin M.

Breast. 2018 Apr;38:144-149. doi: 10.1016/j.breast.2017.12.016. Epub 2018 Jan 8.

12.

Managing cancer care through service delivery networks: The role of professional collaboration in two European cancer networks.

Prades J, Morando V, Tozzi VD, Verhoeven D, Germà JR, Borras JM.

Health Serv Manage Res. 2018 Aug;31(3):120-129. doi: 10.1177/0951484817745219. Epub 2017 Dec 14.

PMID:
29239683
13.

Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES.

Cheang MCU, Bliss JM, Viale G, Speirs V, Palmieri C, Shaaban A, Lønning PE, Morden J, Porta N, Jassem J, van De Velde CJ, Rasmussen BB, Verhoeven D, Bartlett JMS, Coombes RC; PathIES Sub-Committee.

Breast Cancer Res Treat. 2018 Feb;168(1):169-178. doi: 10.1007/s10549-017-4543-7. Epub 2017 Nov 24.

14.

Periodic Trends in the Binding of a Phosphine-Tethered Ketone Ligand to Fe, Co, Ni, and Cu.

Verhoeven DGA, van Wiggen MAC, Kwakernaak J, Lutz M, Klein Gebbink RJM, Moret ME.

Chemistry. 2018 Apr 6;24(20):5163-5172. doi: 10.1002/chem.201703254. Epub 2017 Dec 20.

PMID:
29077236
15.

Differential mucosal IL-10-induced immunoregulation of innate immune responses occurs in influenza infected infants/toddlers and adults.

Verhoeven D, Perry S.

Immunol Cell Biol. 2017 Mar;95(3):252-260. doi: 10.1038/icb.2016.91. Epub 2016 Sep 15.

PMID:
27629065
16.

Metal-ligand cooperation at tethered π-ligands.

Verhoeven DG, Moret ME.

Dalton Trans. 2016 Oct 12;45(40):15762-15778.

PMID:
27460960
17.

Control of influenza infection is impaired by diminished interferon-γ secretion by CD4 T cells in the lungs of toddler mice.

Verhoeven D, Perry S, Pryharski K.

J Leukoc Biol. 2016 Jul;100(1):203-12. doi: 10.1189/jlb.4A1014-497RR. Epub 2016 Jan 28.

18.

Transplanting Diseases from Organ Donors in Western Europe: Fault Liability or Strict Liability?

Broeckx N, Verhoeven D.

Eur J Health Law. 2015 Jun;22(3):207-38.

PMID:
26399044
19.

Team training in obstetrics: A multi-level evaluation.

Sonesh SC, Gregory ME, Hughes AM, Feitosa J, Benishek LE, Verhoeven D, Patzer B, Salazar M, Gonzalez L, Salas E.

Fam Syst Health. 2015 Sep;33(3):250-61. doi: 10.1037/fsh0000148.

PMID:
26348239
20.

Ring-Closing and Cross-Metathesis with Artificial Metalloenzymes Created by Covalent Active Site-Directed Hybridization of a Lipase.

Basauri-Molina M, Verhoeven DG, van Schaik AJ, Kleijn H, Klein Gebbink RJ.

Chemistry. 2015 Oct 26;21(44):15676-85. doi: 10.1002/chem.201502381. Epub 2015 Sep 8.

PMID:
26346291
21.

Reactivation of Human Herpes Virus-6 After Pediatric Stem Cell Transplantation: Risk Factors, Onset, Clinical Symptoms and Association With Severity of Acute Graft-Versus-Host Disease.

Verhoeven DH, Claas EC, Jol-van der Zijde CM, Thijssen JC, Lankester AC, Bredius RG, Putter H, Kroes AC, Egeler RM, Schilham MW, van Tol MJ.

Pediatr Infect Dis J. 2015 Oct;34(10):1118-27. doi: 10.1097/INF.0000000000000824.

PMID:
26132825
22.

Phase II study of weekly paclitaxel/carboplatin in combination with prophylactic G-CSF in the treatment of gynecologic cancers: A study in 108 patients by the Belgian Gynaecological Oncology Group.

Vergote I, Debruyne P, Kridelka F, Berteloot P, Amant F, Honhon B, Lybaert W, Leunen K, Geldhof K, Verhoeven D, Forget F, Vuylsteke P, D'Hondt L, Huizing M, Van den Bulck H, Laenen A.

Gynecol Oncol. 2015 Aug;138(2):278-84. doi: 10.1016/j.ygyno.2015.05.042. Epub 2015 Jun 4.

PMID:
26049123
23.

Prognostic and predictive value of ERβ1 and ERβ2 in the Intergroup Exemestane Study (IES)-first results from PathIES†.

Speirs V, Viale G, Mousa K, Palmieri C, Reed SN, Nicholas H, Cheang M, Jassem J, Lønning PE, Kalaitzaki E, van de Velde CJ, Rasmussen BB, Verhoeven DM, Shaaban AM, Bartlett JM, Bliss JM, Coombes RC; PathIES Sub-Committee.

Ann Oncol. 2015 Sep;26(9):1890-7. doi: 10.1093/annonc/mdv242. Epub 2015 May 22.

24.

Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO).

Vansteenkiste J, Barlesi F, Waller CF, Bennouna J, Gridelli C, Goekkurt E, Verhoeven D, Szczesna A, Feurer M, Milanowski J, Germonpre P, Lena H, Atanackovic D, Krzakowski M, Hicking C, Straub J, Picard M, Schuette W, O'Byrne K.

Ann Oncol. 2015 Aug;26(8):1734-40. doi: 10.1093/annonc/mdv219. Epub 2015 May 4.

PMID:
25939894
25.

Trivalent pneumococcal protein recombinant vaccine protects against lethal Streptococcus pneumoniae pneumonia and correlates with phagocytosis by neutrophils during early pathogenesis.

Xu Q, Surendran N, Verhoeven D, Klapa J, Ochs M, Pichichero ME.

Vaccine. 2015 Feb 18;33(8):993-1000. doi: 10.1016/j.vaccine.2015.01.014. Epub 2015 Jan 15.

PMID:
25597944
26.

THE DUTY TO PERFORM A PATIENT RECALL.

Verhoeven D.

Med Law. 2014 Jul;33(2):91-112.

PMID:
27359010
27.

Divergent mucosal and systemic responses in children in response to acute otitis media.

Verhoeven D, Pichichero ME.

Clin Exp Immunol. 2014 Oct;178(1):94-101. doi: 10.1111/cei.12389.

28.
29.
30.

Vaccination with a Streptococcus pneumoniae trivalent recombinant PcpA, PhtD and PlyD1 protein vaccine candidate protects against lethal pneumonia in an infant murine model.

Verhoeven D, Xu Q, Pichichero ME.

Vaccine. 2014 May 30;32(26):3205-10. doi: 10.1016/j.vaccine.2014.04.004. Epub 2014 Apr 13.

PMID:
24731814
31.

Enhanced innate antiviral gene expression, IFN-α, and cytolytic responses are predictive of mucosal immune recovery during simian immunodeficiency virus infection.

Verhoeven D, George MD, Hu W, Dang AT, Smit-McBride Z, Reay E, Macal M, Fenton A, Sankaran-Walters S, Dandekar S.

J Immunol. 2014 Apr 1;192(7):3308-18. doi: 10.4049/jimmunol.1302415. Epub 2014 Mar 7.

32.

Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial.

Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, Verhoeven D, Pedrini JL, Smirnova I, Lichinitser MR, Pendergrass K, Malorni L, Garnett S, Rukazenkov Y, Martin M.

J Natl Cancer Inst. 2014 Jan;106(1):djt337. doi: 10.1093/jnci/djt337. Epub 2013 Dec 7.

33.

Lower nasopharyngeal epithelial cell repair and diminished innate inflammation responses contribute to the onset of acute otitis media in otitis-prone children.

Verhoeven D, Nesselbush M, Pichichero ME.

Med Microbiol Immunol. 2013 Aug;202(4):295-302. doi: 10.1007/s00430-013-0293-2. Epub 2013 Apr 11.

34.

Chronic stress undermines the compensatory sleep efficiency increase in response to sleep restriction in adolescents.

Astill RG, Verhoeven D, Vijzelaar RL, Van Someren EJ.

J Sleep Res. 2013 Aug;22(4):373-9. doi: 10.1111/jsr.12032. Epub 2013 Feb 9.

35.

Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology.

Garnett SA, Martin M, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, Verhoeven D, Pedrini JL, Smirnova I, Lichinitser MR, Pendergrass K, Lindemann JP, Di Leo A.

Breast Cancer Res Treat. 2013 Feb;138(1):149-55. doi: 10.1007/s10549-012-2395-8. Epub 2013 Feb 3.

36.

Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers.

Seront E, Rottey S, Sautois B, Kerger J, D'Hondt LA, Verschaeve V, Canon JL, Dopchie C, Vandenbulcke JM, Whenham N, Goeminne JC, Clausse M, Verhoeven D, Glorieux P, Branders S, Dupont P, Schoonjans J, Feron O, Machiels JP.

Ann Oncol. 2012 Oct;23(10):2663-70. Epub 2012 Apr 3.

PMID:
22473592
37.

Adenovirus type 35, but not type 5, stimulates NK cell activation via plasmacytoid dendritic cells and TLR9 signaling.

Pahl JH, Verhoeven DH, Kwappenberg KM, Vellinga J, Lankester AC, van Tol MJ, Schilham MW.

Mol Immunol. 2012 May;51(1):91-100. doi: 10.1016/j.molimm.2012.02.119. Epub 2012 Mar 16.

PMID:
22424784
38.

The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma.

Gerlier L, Lamotte M, Awada A, Bosly A, Bries G, Cocquyt V, Focan C, Henry S, Lalami Y, Machiels JP, Mebis J, Straetmans N, Verhoeven D, Somers L.

BMC Cancer. 2010 Nov 23;10:642. doi: 10.1186/1471-2407-10-642.

39.

Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.

Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, Verhoeven D, Pedrini JL, Smirnova I, Lichinitser MR, Pendergrass K, Garnett S, Lindemann JP, Sapunar F, Martin M.

J Clin Oncol. 2010 Oct 20;28(30):4594-600. doi: 10.1200/JCO.2010.28.8415. Epub 2010 Sep 20. Erratum in: J Clin Oncol. 2011 Jun 1;29(16):2293.

PMID:
20855825
40.

Memory CD4 T cells direct protective responses to influenza virus in the lungs through helper-independent mechanisms.

Teijaro JR, Verhoeven D, Page CA, Turner D, Farber DL.

J Virol. 2010 Sep;84(18):9217-26. doi: 10.1128/JVI.01069-10. Epub 2010 Jun 30.

41.

TLR2 engagement on dendritic cells promotes high frequency effector and memory CD4 T cell responses.

Chandran SS, Verhoeven D, Teijaro JR, Fenton MJ, Farber DL.

J Immunol. 2009 Dec 15;183(12):7832-41. doi: 10.4049/jimmunol.0901683.

42.

Enhancing systematic implementation of skills training modules for persons with schizophrenia: three steps forward and two steps back?

van Erp NH, van Vugt M, Verhoeven D, Kroon H.

Psychiatr Rehabil J. 2009 Summer;33(1):50-2. doi: 10.2975/33.1.2009.50.52.

PMID:
19592380
43.

Pulse-oximetry accurately predicts lung pathology and the immune response during influenza infection.

Verhoeven D, Teijaro JR, Farber DL.

Virology. 2009 Aug 1;390(2):151-6. doi: 10.1016/j.virol.2009.05.004. Epub 2009 Jun 2.

44.

Costimulation modulation uncouples protection from immunopathology in memory T cell responses to influenza virus.

Teijaro JR, Njau MN, Verhoeven D, Chandran S, Nadler SG, Hasday J, Farber DL.

J Immunol. 2009 Jun 1;182(11):6834-43. doi: 10.4049/jimmunol.0803860.

45.

Evidence for natural killer cell-mediated protection from metastasis formation in uveal melanoma patients.

Maat W, van der Slik AR, Verhoeven DH, Alizadeh BZ, Ly LV, Verduijn W, Luyten GP, Mulder A, van Hall T, Koning F, Jager MJ, van Bergen J.

Invest Ophthalmol Vis Sci. 2009 Jun;50(6):2888-95. doi: 10.1167/iovs.08-2733. Epub 2009 Feb 21.

PMID:
19234348
46.

Loss of growth factor receptor signaling in the oral mucosa during primary SIV infection may enhance apoptosis and promote pathogenesis.

George MD, Verhoeven D, Sankaran S, Dang AT, Dandekar S.

J Med Primatol. 2008 Dec;37 Suppl 2:55-61. doi: 10.1111/j.1600-0684.2008.00322.x.

PMID:
19187431
47.

Heightened cytotoxic responses and impaired biogenesis contribute to early pathogenesis in the oral mucosa of simian immunodeficiency virus-infected rhesus macaques.

George MD, Verhoeven D, Sankaran S, Glavan T, Reay E, Dandekar S.

Clin Vaccine Immunol. 2009 Feb;16(2):277-81. doi: 10.1128/CVI.00265-08. Epub 2008 Dec 17.

48.

Observational Aranesp Survey to Investigate the Q3W Schedule (OASIS): a prospective observational study of treatment of chemotherapy-induced anaemia with every 3 weeks darbepoetin alfa.

Pat K, Anrys B, Verhulst D, Van Aelst F, Van Eygen K, Galdermans D, Verhoeven D, Polus M, Segers K, Derde MP, Wauters I, Vansteenkiste J.

Support Care Cancer. 2009 Feb;17(2):211-5. doi: 10.1007/s00520-008-0517-y. Epub 2008 Oct 18.

PMID:
18931861
49.

Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer.

Machiels JP, Mazzeo F, Clausse M, Filleul B, Marcelis L, Honhon B, D'Hondt L, Dopchie C, Verschaeve V, Duck L, Verhoeven D, Jousten P, Bonny MA, Moxhon AM, Tombal B, Kerger J.

J Clin Oncol. 2008 Nov 10;26(32):5261-8. doi: 10.1200/JCO.2008.16.9524. Epub 2008 Sep 15.

PMID:
18794543
50.

NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways.

Verhoeven DH, de Hooge AS, Mooiman EC, Santos SJ, ten Dam MM, Gelderblom H, Melief CJ, Hogendoorn PC, Egeler RM, van Tol MJ, Schilham MW, Lankester AC.

Mol Immunol. 2008 Sep;45(15):3917-25. doi: 10.1016/j.molimm.2008.06.016. Epub 2008 Jul 26.

PMID:
18657862

Supplemental Content

Loading ...
Support Center